Completed PHASE3 INTERVENTIONAL NCT00098735

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation

Sponsor: Novartis Pharmaceuticals

Interventions FTY720

Updated 5 times since 2017 Last updated: Nov 16, 2016 Started: Apr 30, 2004 Primary completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00098735, this PHASE3 trial focuses on Kidney Transplantation and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.